查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1590910

頭頸癌診斷市場：按診斷方法和最終用戶分類 - 全球預測 2025-2030

Head & Neck Cancer Diagnostics Market by Diagnostic Method (Bioscopy Screening, Blood Tests, Dental Diagnostic), End User (Diagnostic Centers, Hospitals) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年頭頸癌診斷市場價值為17.4億美元，預計到2024年將達到20.3億美元，複合年成長率為16.78%，到2030年將達到51.6億美元，預計將達到1000萬美元。

頭頸癌診斷市場範圍涵蓋廣泛的診斷技術和工具，用於識別口腔、咽、喉、鼻竇和唾液腺的癌症。這個市場至關重要，因為頭頸癌盛行率不斷上升，需要先進的早期診斷方法來提高治療效果。診斷應用範圍從 CT 和 MRI 掃描等影像檢查到切片檢查、血液測試以及準確識別癌症類型和階段的新分子診斷。最終用途範圍主要包括醫院、診斷實驗室和研究機構，以執行和創新這些診斷程序。

主要市場統計
基準年[2023] 17.4億美元
預測年份 [2024] 20.3億美元
預測年份 [2030] 51.6億美元
複合年成長率（%） 16.78%

診斷工具的技術進步、醫療保健支出的增加以及頭頸癌早期檢測意識的提高對市場成長產生了重大影響。此外，醫療保健基礎設施投資的快速成長，特別是在新興國家，為市場擴張提供了機會。鼓勵市場上的公司專注於個人化醫療和非侵入性診斷技術，例如液態切片和新型生物標記，這些技術可以在最小化患者不適的情況下使用，因為它可以提供準確和快速的結果，因此越來越受歡迎。與生物技術公司合作開發次世代定序技術也可能提供寶貴的機會。

儘管存在這些機遇，但先進診斷設備的高成本、某些地區獲得醫療保健的機會有限以及嚴格的監管通訊協定等挑戰可能會抑製成長。此外，癌症發生和進展的變異性強調需要持續研究以提高診斷準確性和治療結果。最佳創新領域包括人工智慧在診斷中的整合、攜帶式診斷設備的開發以及遠端醫療能力的進步以擴大診斷覆蓋範圍。隨著技術的快速整合和對以患者為中心的醫療保健解決方案的日益重視，這個市場充滿活力，這使得相關人員必須投資於研究和合作以保持競爭力。

市場動態：快速發展的頭頸癌診斷市場的關鍵市場洞察

供需的動態交互作用正在改變頭頸癌診斷市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，並了解消費行為及其對製造成本的影響，並更清楚地了解對採購趨勢的影響。

  • 市場促進因素
    • 全球頭頸癌盛行率
    • 增加政府和私營部門的癌症診斷舉措
    • 頭頸癌診斷的核准增加
  • 市場限制因素
    • 設備高成本，報銷情況不利
  • 市場機會
    • 診斷方法的新進展與創新
    • 為腫瘤學進步提供大量研究經費
  • 市場挑戰
    • 缺乏訓練有素的專業人員

波特五力策略工具引領頭頸癌診斷市場

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢、解決弱點並避免潛在的挑戰，以確保更強大的市場地位。

PESTLE分析：了解外部對頭頸癌診斷藥物市場的影響

外部宏觀環境因素在塑造頭頸癌診斷市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解頭頸癌診斷藥物市場的競爭狀況

對頭頸癌診斷市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 頭頸癌診斷市場定位矩陣供應商績效評估

FPNV定位矩陣是評估頭頸癌診斷市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，描繪頭頸癌診斷市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，頭頸癌診斷市場的策略分析至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 全球頭頸癌盛行率
      • 政府和私營部門在癌症診斷上加強力
      • 提高頭頸癌診斷藥物核准率
    • 抑制因素
      • 高成本，報銷場景不利
    • 機會
      • 診斷調查方法的新進展與創新
      • 腫瘤學進展的主要研究經費
    • 任務
      • 缺乏訓練有素的專業人員
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章依診斷方法分類的頭頸癌診斷藥物市場

  • 生物鏡篩檢
  • 驗血
  • 牙科診斷
  • 診斷影像
  • 內視鏡檢查

第7章頭頸癌診斷市場：依最終用戶分類

  • 診斷中心
  • 醫院

第8章北美和南美頭頸癌診斷藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章亞太地區頭頸癌診斷藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章歐洲、中東和非洲頭頸癌診斷藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • AbbVie Inc.
  • AdDent, Inc.
  • Bristol Myers Squibb Company
  • Canon Inc.
  • Carestream Health Inc. by Koninklijke Philips NV
  • Esaote SpA
  • FUJIFILM Holdings Corporation
  • General Electric Company
  • KARL STORZ SE & Co. KG
  • Merck KGaA
  • Olympus Corporation
  • Optim LLC
  • Shimadzu Corporation
  • Siemens AG
  • Xoran Technologies LLC
Product Code: MRR-437E9896A540

The Head & Neck Cancer Diagnostics Market was valued at USD 1.74 billion in 2023, expected to reach USD 2.03 billion in 2024, and is projected to grow at a CAGR of 16.78%, to USD 5.16 billion by 2030.

The scope of the Head & Neck Cancer Diagnostics market encompasses a wide array of diagnostic techniques and tools utilized in identifying cancers of the oral cavity, pharynx, larynx, paranasal sinuses, and salivary glands. This market is crucial due to the rising prevalence of head and neck cancers, necessitating advanced and early diagnostic methods to enhance treatment efficacy. Diagnostics applications range from imaging tests, such as CT and MRI scans, to biopsy procedures, blood tests, and emerging molecular diagnostics that offer precision in identifying cancer type and stage. The end-use scope primarily includes hospitals, diagnostic laboratories, and research institutions that perform and innovate these diagnostic procedures.

KEY MARKET STATISTICS
Base Year [2023] USD 1.74 billion
Estimated Year [2024] USD 2.03 billion
Forecast Year [2030] USD 5.16 billion
CAGR (%) 16.78%

Market growth is significantly influenced by technological advancements in diagnostic tools, increased healthcare expenditure, and heightened awareness about the early detection of head & neck cancers. Moreover, the surge in healthcare infrastructure investments, particularly in emerging economies, presents a lucrative opportunity for market expansion. Companies in the market are encouraged to focus on personalized medicine and non-invasive diagnostic techniques, such as liquid biopsies and novel biomarkers, which are gaining traction due to their ability to offer accurate and quick results with minimal discomfort to patients. Partnerships with biotechnology firms for the development of next-generation sequencing techniques can also provide valuable opportunities.

Despite these opportunities, challenges such as the high costs of advanced diagnostic equipment, limited healthcare access in certain regions, and stringent regulatory protocols can impede growth. Furthermore, variability in cancer presentation and progression underscores the necessity for continuous research to improve diagnostic accuracy and treatment outcomes. The best areas for innovation include the integration of artificial intelligence in diagnostics, development of portable diagnostic devices, and advancements in telemedicine capabilities to extend diagnostic reach. This market is dynamic, driven by rapid technological integration and a growing emphasis on patient-centric healthcare solutions, making it essential for stakeholders to invest in research and collaboration to remain competitive.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Head & Neck Cancer Diagnostics Market

The Head & Neck Cancer Diagnostics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Prevalence of head and neck cancer worldwide
    • Rise in government and private body initiatives for cancer diagnostics
    • Increased approval for head & neck cancer diagnostics
  • Market Restraints
    • High cost of the devices and unfavorable reimbursement scenarios
  • Market Opportunities
    • New advancements and innovations in diagnostic methodology
    • Large research funding in oncological advancement
  • Market Challenges
    • Dearth of trained professionals

Porter's Five Forces: A Strategic Tool for Navigating the Head & Neck Cancer Diagnostics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Head & Neck Cancer Diagnostics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Head & Neck Cancer Diagnostics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Head & Neck Cancer Diagnostics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Head & Neck Cancer Diagnostics Market

A detailed market share analysis in the Head & Neck Cancer Diagnostics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Head & Neck Cancer Diagnostics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Head & Neck Cancer Diagnostics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Head & Neck Cancer Diagnostics Market

A strategic analysis of the Head & Neck Cancer Diagnostics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Head & Neck Cancer Diagnostics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., AdDent, Inc., Bristol Myers Squibb Company, Canon Inc., Carestream Health Inc. by Koninklijke Philips N.V., Esaote S.p.A., FUJIFILM Holdings Corporation, General Electric Company, KARL STORZ SE & Co. KG, Merck KGaA, Olympus Corporation, Optim LLC, Shimadzu Corporation, Siemens AG, and Xoran Technologies LLC.

Market Segmentation & Coverage

This research report categorizes the Head & Neck Cancer Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Diagnostic Method, market is studied across Bioscopy Screening, Blood Tests, Dental Diagnostic, Diagnostic Imaging, and Endoscopy Screening.
  • Based on End User, market is studied across Diagnostic Centers and Hospitals.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Prevalence of head and neck cancer worldwide
      • 5.1.1.2. Rise in government and private body initiatives for cancer diagnostics
      • 5.1.1.3. Increased approval for head & neck cancer diagnostics
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of the devices and unfavorable reimbursement scenarios
    • 5.1.3. Opportunities
      • 5.1.3.1. New advancements and innovations in diagnostic methodology
      • 5.1.3.2. Large research funding in oncological advancement
    • 5.1.4. Challenges
      • 5.1.4.1. Dearth of trained professionals
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Head & Neck Cancer Diagnostics Market, by Diagnostic Method

  • 6.1. Introduction
  • 6.2. Bioscopy Screening
  • 6.3. Blood Tests
  • 6.4. Dental Diagnostic
  • 6.5. Diagnostic Imaging
  • 6.6. Endoscopy Screening

7. Head & Neck Cancer Diagnostics Market, by End User

  • 7.1. Introduction
  • 7.2. Diagnostic Centers
  • 7.3. Hospitals

8. Americas Head & Neck Cancer Diagnostics Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Head & Neck Cancer Diagnostics Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Head & Neck Cancer Diagnostics Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. AdDent, Inc.
  • 3. Bristol Myers Squibb Company
  • 4. Canon Inc.
  • 5. Carestream Health Inc. by Koninklijke Philips N.V.
  • 6. Esaote S.p.A.
  • 7. FUJIFILM Holdings Corporation
  • 8. General Electric Company
  • 9. KARL STORZ SE & Co. KG
  • 10. Merck KGaA
  • 11. Olympus Corporation
  • 12. Optim LLC
  • 13. Shimadzu Corporation
  • 14. Siemens AG
  • 15. Xoran Technologies LLC

LIST OF FIGURES

  • FIGURE 1. HEAD & NECK CANCER DIAGNOSTICS MARKET RESEARCH PROCESS
  • FIGURE 2. HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHOD, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHOD, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. HEAD & NECK CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. HEAD & NECK CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. HEAD & NECK CANCER DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. HEAD & NECK CANCER DIAGNOSTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY BIOSCOPY SCREENING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY DENTAL DIAGNOSTIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY ENDOSCOPY SCREENING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. AMERICAS HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 19. ARGENTINA HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 20. ARGENTINA HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 21. BRAZIL HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 22. BRAZIL HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 23. CANADA HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 24. CANADA HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 25. MEXICO HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 26. MEXICO HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 27. UNITED STATES HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 28. UNITED STATES HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 29. UNITED STATES HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 30. ASIA-PACIFIC HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 31. ASIA-PACIFIC HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 32. ASIA-PACIFIC HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 33. AUSTRALIA HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 34. AUSTRALIA HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 35. CHINA HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 36. CHINA HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 37. INDIA HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 38. INDIA HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 39. INDONESIA HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 40. INDONESIA HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 41. JAPAN HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 42. JAPAN HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 43. MALAYSIA HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 44. MALAYSIA HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 45. PHILIPPINES HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 46. PHILIPPINES HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 47. SINGAPORE HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 48. SINGAPORE HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 49. SOUTH KOREA HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 50. SOUTH KOREA HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 51. TAIWAN HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 52. TAIWAN HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 53. THAILAND HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 54. THAILAND HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 55. VIETNAM HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 56. VIETNAM HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 57. EUROPE, MIDDLE EAST & AFRICA HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 58. EUROPE, MIDDLE EAST & AFRICA HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 59. EUROPE, MIDDLE EAST & AFRICA HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 60. DENMARK HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 61. DENMARK HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 62. EGYPT HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 63. EGYPT HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 64. FINLAND HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 65. FINLAND HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 66. FRANCE HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 67. FRANCE HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 68. GERMANY HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 69. GERMANY HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 70. ISRAEL HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 71. ISRAEL HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 72. ITALY HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 73. ITALY HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 74. NETHERLANDS HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 75. NETHERLANDS HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 76. NIGERIA HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 77. NIGERIA HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 78. NORWAY HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 79. NORWAY HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 80. POLAND HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 81. POLAND HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 82. QATAR HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 83. QATAR HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 84. RUSSIA HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 85. RUSSIA HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 86. SAUDI ARABIA HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 87. SAUDI ARABIA HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH AFRICA HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH AFRICA HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 90. SPAIN HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 91. SPAIN HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 92. SWEDEN HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 93. SWEDEN HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 94. SWITZERLAND HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 95. SWITZERLAND HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 96. TURKEY HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 97. TURKEY HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED ARAB EMIRATES HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED ARAB EMIRATES HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED KINGDOM HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 101. UNITED KINGDOM HEAD & NECK CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 102. HEAD & NECK CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 103. HEAD & NECK CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023